Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears

Why did TSMC's profit surge on AI chip demand? How will Stellantis' US expansion impact Canada? What does OpenAI's $1tn plan mean for AI? Why is Nestle cutting thousands of jobs now? How did BlackRock-Nvidia's $40B data center deal form? What caused Bitcoin and crypto market volatility today? Why is the US pushing Japan to stop Russian oil imports?

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears

benzinga.com/news/health-care/25/10/48205017/vor-bios-collaborator-delivers-positive-results-for-telitacicept-in-autoimmune-disorder-that-imp

Vor Bio (NASDAQ:VOR) stated on Tuesday that its collaborator, RemeGen Co. Ltd., had shared 48-week results from its Phase 3 study conducted in China evaluating telitacicept in primary Sjögren’s disease.
Sjögren’s disease is a chronic autoimmune condition in which overactive B cells drive…

This story appeared on benzinga.com, 2025-10-14 16:22:03.